Feedback / Questions
MRTX1133 - BMS
Effects of the KRAS (G12D)-selective inhibitor MRTX1133 in ovarian mucinous carcinoma
(ESGCT 2026)
-
Sep 11, 2026 -
Abstract #P0445;
No abstract available
Mucinous carcinoma • Oncology • Ovarian Cancer
•
KRAS
https://www.esgctcongress.com/poster-list
Ryota Watano
Sep 11, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next